Last updated on June 2018

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Brief description of study

This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Clinical Study Identifier: NCT02962895

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Sasebo-city, Japan
  Connect »